News

Congrats to Calvin for the acceptance of his paper in eLife! The title of the paper is "MEIS-mediated suppression of human prostate cancer growth and metastasis through HOXB13-dependent regulation of proteoglycans." This was a great team effort, and thank you to everyone who contributed.

Check out the paper here: https://elifesciences.org/articles/53600

Dr. Perike's project entitled "Role of MEIS Proteins as HOXB13-Dependent Inhibitors of Prostate Cancer Metastasis and Androgen Receptor Signaling” received a 2-year award from the AUA and Urology Care Foundation. Congrats!

https://www.auanet.org/research/research-funding/aua-funding/research-scholar-awards/2020-2022-research-scholars

Congrats to Erin et al. for her recent paper published in Stem Cells. URL here

Key Findings:

• Lineage-tracing of Sox2-positive cells in the prostate demonstrates that they are long-lived and multipotent.
• Sox2-positive cells survive castration, and contribute to epithelial regeneration.
• Persisting Sox2-positive luminal cells are castration-resistant.

Congrats to Raj et al. for their recent paper published in Clinical Cancer Research. URL here

Key Findings:

• 11% of prostate tumors are MEIS-positive; MEIS-positive tumors are associated with decreased PSA-recurrence and metastasis.
• MEIS high tumors are associated with decreased proliferation, increased adhesion, and increased differentiation.
• Knockdown of both MEIS1 and MEIS2 in prostate cancer cells renders them more tumorigenic.

Congrats to Erin et al. for their recent paper published in AJP. URL here

Key Findings:

• Longitudinal MRI quantified prostatic enlargement of mouse prostates treated with combined testosterone + estrogen.
• Enlarged prostates did not have increased immune cell invasion, but did have significantly decrease rates of cell death.